logo-loader
viewBed Bath & Beyond Inc.

Bed Bath & Beyond, Horizon Global, Telenav, Ford and more - AFTER HOURS

Proactive takes a look at what was moving the dial after hours in New York

1513860728_santainNewYork.jpg
Ho ho.. Proactive takes a look at after hours trade in New York

Bed Bath & Beyond Inc (NASDAQ:BBBY) was making waves after the bell on Wednesday.

The home retailer initially jumped 7% but then went lower, shedding nearly 5%  to US$23.36 in New York, after posting third quarter results.

 

Discounting and promotions helped prevent sales falling but net income halved in the three months, compared to the same period last year.

 

Meanwhile, PG&E (NYSE:PCG) saw shares plunge over 12% at US$44.85 in extended trade as the natural gas giant revealed it would suspend its quarterly dividend, amid uncertainty related to the wildfires in the state of California.

Also, Horizon Global Corp (NYSE:HZN) shares gained 1.6% after the bell to stand at US$14.60 each.

The towing equipment company announced it settled a four-year-old dispute with rival Hopkins over patent rights to electronic brake controllers. It means, Hopkins will pay Horizon for a license on the patented controller.

Last but not least, Telenav Inc (NASDAQ:TNAV) shares added over 5% to US$ 5.05 after the in-car navigation and marketing company raised its second-quarter earnings and revenue guidance.

It comes after Ford Motor Company (NYSE:F), whose shares added 0.24% to US$12.75 in extended deals, extended an existing  agreement with Telenav until 2020.

The automaker said it will also use Telenav's technology for its vehicles in North America.

Quick facts: Bed Bath & Beyond Inc.

Price: 12.99 USD

NASDAQ:BBBY
Market: NASDAQ
Market Cap: $1.64 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

10 hours, 46 minutes ago

2 min read